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Female mice exposed to soy isoflavones (ISO) during early postnatal life have improved bone outcomes at adulthood. Since long-lasting effects may be
mediated by DNA methylation, we hypothesized that providing supplemental folic acid (FA), a methyl donor, during early life, would enhance the positive effect
of ISO to bone health. Bone-specific gene expression patterns were studied to understand potential mechanisms. CD-1 dams (n=36) were randomized to
adequate or supplemental levels of FA (2 or 8 mg/kg diet) during pregnancy and lactation, and offspring received corn oil or ISO (7 mg/kg body weight/d) from
postnatal day 1 to 10. From weaning, pups were fed an adequate FA diet and were studied to 4 months of age. Female offspring exposed to supplemental FA+ISO
had higher bone mineral density (BMD), trabecular connectivity and peak load at the lumbar spine compared to females exposed to adequate FA. Female
offspring exposed to adequate FA+ISO or supplemental FA had higher (Pb.05) BMD and greater resistance to fracture at the lumbar spine and the femur; higher
trabecular connectivity at the lumbar spine; and lower expression of DNA methyltransferase 3a (Dnmt3a) and neuropeptide Y (NPY) in the femur compared to
mice exposed to adequate FA. In addition, only mice exposed to adequate FA+ISO had microstructural improvements at the femur neck and higher serum
osteoprotegrin (OPG) and insulin growth factor-I (IGF-I). In summary, exposure to supplemental FA did not enhance the positive effect of ISO in bone. However,
exposure to adequate FA+ISO or supplemental FA improved bone at least in part by suppressing Dnmt3a and NPY.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Bone development; DNA methyltransferase; Folic acid; Female CD-1 mice; Neuropeptide Y; Soy isoflavones.1. Introduction
Diet during early life can inﬂuence the development of physiological
and endocrine systems in ways that affect the prevalence of noncommu-
nicable diseases [1–3]. We have previously shown that female mice
exposed to adequate folic acid+soy isoﬂavones (adequate FA+ISO)
during early postnatal life, at levels similar to that of infants consuming
soy protein formula [4], have higher bone mineral density (BMD),
improved trabecular connectivity and greater resistance to fracture at
adulthood [5–9], as well as attenuated deterioration of bone tissue afterAbbreviations: adeq, adequate; BMC, bone mineral content; BMD, bone
mineral density; bw, body weight; CON, control; DEXA, dual energy x-ray
absorptiometry; Dnmt3a, DNA methyltransferase 3a; FA, folic acid; IGF-I
insulin growth factor-I; ISO, soy isoﬂavones; NPY, neuropeptide Y; OPG
osteoprotegrin; supp, supplemental
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.under tovariectomy compared to females exposed to adequate FA alone [7].
However, the mechanism has not been elucidated.
Soy isoﬂavones are bioactives that canprogramepigenetic patterns
[10]. Studies using agouti mice have shown that dams fed a diet rich in
genistein, themost abundant ISO in soy protein, during pregnancy and
lactation give birth to offspring that have hypermethylated CpG
islands in the promoter of the agouti gene, higher prevalence of
pseudo-agouti phenotype and a lower incidence of obesity at 15
months of age compared to control animals [10]. Postnatal exposure to
ISO also stimulates hypermethylation of speciﬁc repetitive elements
that coincidewith signiﬁcant down-regulation of estrogen-responsive
genes involved in hematopoiesis and bone marrow cell development
[11]. Thus, it is possible that skeletal improvements at adulthood,
induced by early life exposure to ISO, are in part mediated by
reprogramming of DNA methylation patterns in the epigenome.
DNA methylation is driven by a group of enzymes called DNA
methyltransferases that recognize CpG dinucleotides of palindromic
sequences and catalyze the transfer of one-carbon group from a
methyl donor to the cytosine residue. As such, changes in the
expression of DNA methyltransferase or the availability of methyl
donors/acceptors can alter DNA methylation patterns. To date, three
DNA methyltransferases have been identiﬁed [12]. DNA methyltrans-
ferase-1 (Dnmt-1) is responsible for maintaining patterns of CpGhe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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de novo methyltransferases that set up DNA methylation patterns
early in development. In 4-week-old rats injected with human
neuroblastoma SK-N-SH cells that had been isolated from toddlers,
treatment with genistein enhanced the expression of tumor suppres-
sor CD5 and p53 by down-regulating the expression of Dnmt-3b [13].
Suppression of Dnmt-3a has also been observed in uterine tissue of
mice exposed to diethylstilbestrol (an environmental estrogen)
during early life [14]. DNA methyltransferases use S-adenosyl
methionine (SAM) as the methyl donor for DNA. In the rate-limiting
step of the SAM cycle, methylenetetrahydrofolate reductase (MTHFR)
irreversibly reduces a derivative of FA 5,10-methylenetetrahydrofo-
late to 5-methyltetrahydrofolate. As such, the availability of FA has an
important role in howDNAmethyltransferasesmodulatemethylation
patterns. The combined effect of administering FA with ISO has been
demonstrated in a study of pregnant rats [15]. In utero exposure to FA
(0.7mg/kg, a level lower than in the control AIN93Gdiet) and ISO (160
mg/kg) supported post-neural tube closure to a greater extent than
either treatment alone [15]. In line with these ﬁndings, we reported
that early-life exposure to adequate FA (2 mg/kg)+ISO [7 mg/kg of
bodyweight (bw)] but not supplemental FA (8mg/kg)+ISO (7mg/kg
of bw) results in higher BMD and greater resistance to fracture at the
femur and lumbar spine in male CD-1 mice [16]. Based on our
published studies, female mice have a more pronounced response to
environmental estrogens (i.e. diethylstilbestrol and ISO) than males
[6,7,17] so female mice were studied to elucidate the mechanism by
which FA and ISO modulate bone development.
To prevent pregnancy-induced anemia and to correct abnormal
folate metabolism or subtle folate inadequacy that may result in
abnormal fetal development, women of child-bearing age are encou-
raged to eat folate-rich foods and take a supplement containing 400 μg
of FA [18]. In addition, many countries, including the United States and
Canada, have introduced mandatory folate fortiﬁcation of grain
products to ensure that all women of child-bearing age have adequate
levels of folate before getting pregnant. Due to these initiatives, many
women of childbearing age have higher (N906 nmol/L) than recom-
mended folate concentrations [19]. If some of these women feed their
neonates with soy protein formula that are fortiﬁedwith FA (2-4mg/L)
and naturally contain high amounts of ISO (32–47 mg/L) [20,21] their
infants may have markedly higher concentration of circulating FA (2.3
fold higher) and ISO (10 fold higher) than infants fed breast milk or
cow’s milk formula [20–22]. Therefore, there is an ongoing need to
characterize how early life exposure to FA and ISO affects growth and
development. The purpose of this study was to determine if providing
supplemental FA, amethyl donor, during early life, can enhance the ISO-
induced beneﬁts to bone health. This study also determined bone-
speciﬁc gene expression patterns to elucidate potential mechanisms.2. Methods
2.1. Animals and treatment
Seven-week-old male and female CD-1 mice (Charles River
Canada) housed in the Department of Comparative Medicine at the
University of Toronto under standard environmental conditions (23°C,
50%humidity, 12h:12h light–dark cycle)were randomized to anamino
acid based diet (Dyets, Bethlehem, PA, USA) fortiﬁed with 2 or 8 mg of
FA/kg and devoid of ISO. The amino acid diet was used because it is the
only rodent diet that does not contain any natural folate, allowing
investigators to more tightly control the level of FA within a diet. The
diet containing 2 mg of FA was used to represent the basal dietary
requirement for rodents while [23], the 8 mg of FA diet was used to
mimic the amount of FA that pregnant women may obtain by
consuming FA supplements and FA-fortiﬁed foods; this supplementallevel of FA has been shown to provide a degree of chemoprevention
against colorectal cancer in rodent models [24–27].
After one week of adaptation to the environment and diet, mice
were mated harem style. Once females were identiﬁed as being
pregnant they were housed in individual cages under standard
environmental conditions (23°C, 50% humidity, 12:12h light-dark
cycle), and remained on their respective diets. Water was provided ad
libitum. Offspring of dams that delivered 8–12 pups on the same day
were fed the same FA diet and were cross-fostered by assigning a
maximum of one male and one female pup from each dam to a litter.
Cross-fostered litters on supplemental or adequate FA diet were then
randomized to ISOor corn oil treatment. Control pups received corn oil
as it is used as the vehicle for ISO [6–8]. The ISO groups received a daily
dose containing 0.010 mg of daidzein and 0.025 mg of genistein per
pup (7 mg/kg bw/day). This dose resembles the concentration of
daidzein and genistein in infants fed soy protein formula [4,6]. All ISO
mixtures were prepared fresh prior to treatment by being solubilized
in 1 ml of dimethyl sulfoxide (DMSO) and suspended in corn oil.
Treatments were administered in the morning from postnatal day
(PND) 1 to 10 via daily subcutaneous injections using a 3/10 cc insulin
syringe with a 30 gauge needle and a 12.7 mm needle length. The 10-
day duration of exposure was selected to target the stage of
development when CD-1 mice have low concentrations of endoge-
nous sex steroids and there is a probability of inducing programming
effects at both the femur and lumbar spine [28]. The total volume of
treatment was 20 μl. At weaning (PND 21), all female offspring were
housed 3-4 per cage and fed an amino acid diet containing 2mg of FA/
kg. Body weight of offspring was measured at birth, 7 and 21 days of
age, and subsequently every week until 16 weeks of age using an
electronic scale (Denver Instrument XP-1500). For time points where
there was a statistically signiﬁcant change in body weight between
groups the percent difference was calculated. The mean body weight
gain of each experimental group was calculated by subtracting the 4
week bodyweightmeasures from the 16week bodyweightmeasures.
At 6 weeks of age, a subset of mice (n=6/group) was euthanized by
carbon dioxide and cervical dislocation, to extract RNA from femurs
and perform microarray analyses. All remaining females were
euthanized at age 16 weeks. The offspring groups were supplemental
folic acid+isoﬂavones (supplemental FA+ISO); adequate folic acid+
isoﬂavones (adequate FA+ISO); supplemental folic acid (supplemen-
tal FA) and adequate folic acid (adequate FA).
All protocols for animal use and treatment were approved by the
University of Toronto Animal Care Committee andwere in compliance
with the guidelines of the Canadian Council on Animal Care [29].
2.2. BMD of femurs and LV1-LV3
Tomeasure bonemineral density (BMD), femurs and intact lumbar
vertebrae (LV1-LV3) stored at−80°Cwere analyzed usingdual energy
x-ray absorptiometry (DEXA) (pSabre, Orthometrix,White Plains, NY,
USA) and a specialized software program (Host Software Version:
3.9.4; Scanner Software Version: 1.2.0) as previously described [6,7,9].
Scans were conducted in air at room temperature using a speed of 2
mm/min and a resolution of 0.01 × 0.01 mm.
2.3. Peak load of femurs and LV2
Femurs and LV2 were hydrated in 0.9% saline solution for 3 hrs at
room temperature. Using an electronic balance (Sartorius AG,
Goettingen, Germany) the weight of the femur and LV2 was
determined. Femur length was measured, from the proximal tip of
the femoral head to the distal tip of the medial condyle, using
electronic precision calipers (Cedarlane Laboratories, Hornby, ON,
Canada). At the femur midpoint, anterior-posterior and mediolateral
width was measured. To determine peak load, the maximal force a
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femur midpoint, a materials testing system (Model 4442, Intron,
Canton, MA, USA) and specialized software (Series IX Automated
Materials Tester, Version 8.15.00) were used as previously described
[6,7,9,30]. Peak load was identiﬁed as the ﬁrst peak of the load-
displacement curve.
2.4. Microarchitecture of femur and LV4
The 3D microarchitecture of femur neck and lumbar spine were
evaluated using a high resolution (8 μm) μCT imaging system (GE
Healthcare System, Model # MS0900325-0010). Scans were conduct-
ed in water and used an x-ray tube source of 80kV and an x-ray
intensity of 80 μA. During scanning, a 1 mm thick aluminum ﬁlter was
employed to minimize beam hardening effects, and a bath was placed
over top of the specimenholder to improve image quality and increase
overall accuracy by preventing interference of the refracted wave-
length of x-rays with unrefracted x-rays. For each scan, 500
radiographic projections were acquired over an angular range of
180° (angular step of 45°) with a ﬁxed exposure time of 3 sec per
frame. From 2D radiographic projections, a 3D structural image was
reconstructed (voxel size of 0.014mm3) using a 3DGaussianﬁlter that
partly suppresses the volume noise. Femur neck was analyzed from
the bottom edge of the femur head to the narrowest part of the femur
shaft by selecting aﬁxed region of 1.5mm. Similarly, LV4was analyzed
by selecting a ﬁxed region of 1 mm at LV4 midpoint. Unbiased 3D
microstructural properties of trabecular bone (i.e. trabecular bone
volume, BV/TV; trabecular surface area, BS/BV; trabecular thickness,
Tb.Th; trabecular number, Tb.N; trabecular separation, Tb.Sp) were
calculated using methods based on distance transformation of the
binarized images.
2.5. Biochemical analyses
Serum adrenocorticotropic hormone (ACTH), osteoprotegrin
(OPG), receptor activator for nuclear factor kB ligand (RANKL),
osteocalcin, insulin-like growth factor (IGF-I) and IGF binding proteins
(IGFBP-1,2,3,5,6,7) were measured using commercially available kits
(Milliplex MAP, based on the Luminex xMAP technology by Millipore,
Billerica, MA, USA).
2.6. Bone microarray and real-time reverse transcription polymerase
chain reaction
After aspiration of bone marrow, total RNA was isolated from fresh
femurs using Trizol reagent (Invitrogen, San Diego, CA, USA) according
to the manufacturer’s protocol. RNA integrity of isolated RNA was
assessed by Agilent 2100 Bioanalyzer on the RNA 600 Nano kit (Agilent
Technologies, Santa Clara, CA, USA), and only samples with an RNA
Integrity Number (RIN) of 8 or higher were used for analyses. In total,
the RNA of 24 samples, 6 from each group were analyzed. The Illumina
TotalPrep-96 RNA Ampliﬁcation kit (Ambion, Wilmington, DE, USA)
was used for RNA ampliﬁcation of each sample according to
manufacturer’s instructions. In short, 200 ng of RNA sample was
reversed transcribedwith anoligo(dT) primerwith a T7promoter using
ArrayScript reverse transcriptase. cDNA generated from this reaction
then underwent a second synthesis and cleanup to generate a template
for in vitro transcriptionwith T7 RNA Polymerase. In vitro transcription
ampliﬁcation generates biotinylated, amtisense RNA copies of each
mRNA in the sample (cRNA) that was then used for hybridization with
Illumina beadchips. For each sample, 1.5 ug of the generated cRNA was
hybridized onto the Mouse WG-6 V2 Beadchips (Illumina, San Diego,
USA) according to manufacturer’s protocol. All samples passed
Illumina's sample dependent and independent quality control metrics.
Microarray data was processed using the Bioconductor R (v2.14.1)framework and Lumi package (www.bioconductor.org) and was
imported into GeneSpring v11.5.1 for analysis. During import, data
was normalized using a standard quantile-based (for Illumina arrays)
normalization followed by a “per probe” median-centered normaliza-
tion. All data analysis and visualization were performed on log2
transformed data. A total of 45281probes are represented on theMouse
WG-6v2r3 array. For statistical tests, data was ﬁrst ﬁltered to remove
the confounding effect probes that showed no signal. Only probes that
were in the upper 80th percentile of the distribution of intensities in
100% of any of the four groups were allowed to pass through this
ﬁltering. The ﬁltered set contained 30269 probes. A threshold of 1.5 fold
change was used to ﬁnd a list of differentially expressed genes among
different FA treatments with and without ISO. Microarray experiments
were performed at the University Health Network (UHN) Microarray
Centre, Toronto, Canada.
To validate the results obtained by the Mouse WG-6 V2 Beadchip
and quantify expression of DNA methyltransferases (Dnmt1, Dnmt3a
and Dnmt3b), we performed TaqMan veriﬁcation using One-Step Plus
sequence detection system (Applied Biosystems, Foster City, CA, USA).
The TaqMan probe assays (Applied Biosystems, Foster City, CA) were
carried out in a ﬁnal 20 μl reaction volume using 1 μl of commercially
available primermix, 10 ul of TaqManUniversalMasterMix and 2 μl of
sample extracted DNA. Thermal cycling proceeded with 40 cycles of
95°C for 15 s and 60°C for 1 min. Input RNA amounts were calculated
with relative standard curves for both the mRNAs of interest and β-
actin (Actb). In all cases reactions were performed in triplicates using
the same six independent samples of bone RNA.
2.7. Statistical analyses
Statistical analyses were performed using SigmaStat (Version 3.5,
Jandel Scientiﬁc). Data are expressed as mean±S.E.M. One-way
ANOVA followed by a Student Newman–Keul’s post hoc test was
used to analyze differences in body weight at birth. Repeated
measures two-way ANOVA followed by a Student-Newman-Keul's
post hoc test were used to analyze difference in body weight at one
week intervals from 3 to 16 weeks of age. For microarray analyses, an
ANOVA using an FDR Benjamini and Hochberg multiple testing
correction threshold of qb.05 was performed. For all other measures,
two-way ANOVA was used with FA and ISO as the main effects. For
data that did not follow a normal distribution, a Kruskal-Wallis two-
way ANOVA on ranks followed by Student Newman–Keul’s post hoc
test was used to determine differences among groups. Statistical
signiﬁcance was determined as P≤.05. For microarray analyses, an
ANOVA using an FDR Benjamini and Hochberg multiple testing
correction threshold of qb.05 was performed.
3. Results
3.1. Early life exposure to ISO promotes weight gain in female mice when
given in combination with an adequate but not supplemental level of FA
From birth through weaning there were no signiﬁcant differences
in body weight among groups (Fig. 1). There were also no signiﬁcant
differences in body weight between female mice exposed to
supplemental FA+ISO, supplemental FA alone or adequate FA from
weaning through 16 weeks of age (Fig. 1B). In contrast, female mice
exposed to adequate FA+ISO had 10–20% higher (Pb.05) body weight
from4 through 16weeks of age than femalemice exposed to adequate
FA alone (Fig. 1A). Themeanweight gain fromweaning to 16weeks of
age was not signiﬁcantly different between female mice exposed to
supplemental FA+ISO (25.6±1.60 g), supplemental FA alone (25.0±
1.48 g) or adequate FA (24.8±0.94 g) but, females exposed to
adequate FA+ISO (28.2±1.31 g) had a slightly higher gain in body
weight (P=.055) than females exposed to adequate FA. For all groups,
Fig. 1. Bodyweight frombirth through 16weeks of age of femalemicewhosemothers’were fed adequate (A) or supplemental (B) FA during pregnancy and lactation, andwho fromPND
1-10were treatedwith subcutaneous injections of corn oil or ISO. The shaded area represents the normal growth range of CD-1mice [31]. Values are expressed asmeans±S.E.M.,n=12–
18 *Different from corresponding corn oil treated females, Pb.05. The percentages represent the percent difference in body weight between groups at the speciﬁc age. Abbreviations: FA –
folic acid; ISO – soy isoﬂavones.
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the shaded area) [31].
3.2. Early life exposure to supplemental FA+ISO, adequate FA+ISO or
supplemental FA alone has a positive effect on BMD and bone strength of
femurs and lumbar spine in female mice at adulthood
There was an overall interaction effect (FA × ISO) on femur and
lumbar spine BMD and peak load. Female offspring exposed to
supplemental FA+ISOhad higher (Pb.05) LV1-3 BMD and peak load of
femur midpoint and LV2 than those exposed to adequate FA (Fig. 2).
However, exposure to supplemental FA+ISO did not result in higher
BMD or greater bone strength at the femur or lumbar spine comparedFig. 2. BMD and peak load of femur (A) and lumbar vertebrae (B) from 4-month old female CD
lactation, and who from PND 1-10 were treated with subcutaneous injections of corn oil or ISO
differ, Pb.05. Abbreviations: CON – control; FA – folic acid; ISO – soy isoﬂavones.with exposure to adequate FA+ISO or supplemental FA. Female
offspring exposed to adequate FA+ISO or supplemental FA had higher
(Pb.05) BMD of whole femur and LV1-3, and higher (Pb.05) peak load
at the femur midpoint when compared to mice exposed to adequate
FA (Fig. 2).
3.3. Early life exposure to adequate FA+ISO or supplemental FA alone
results in higher BV/TV and trabecular number, and lower trabecular
separation in female mice at adulthood
Exposure to FA and ISO both had an independent effect on BV/TV of
LV4. Female offspring exposed to supplemental FA (P=.001) had
higher BV/TV of LV4 than females exposed to adequate FA (Table 1).-1 mice whose mothers’ were fed adequate or supplemental FA during pregnancy and
. Values are expressed as mean±S.E.M., n=12–18/group. Bars without a common letter
Table 1
Trabecular bone parameters of female CD-1 mice whose mothers were fed adequate or
supplemental FA during pregnancy and lactation, andwho from PND 1-10were treated
with subcutaneous injections of corn oil or ISO
FA (mg) Treatment Statistical analyses
CON ISO FA ISO FA ×
ISO
LV 4
BV/TV, % Adequate 29.8±1.24 33.9±1.24 .001 b.001 NS
Supplemental 33.4±1.16 39.1±1.24
BS/BV,
mm2/mm3
Adequate 39.9±3.25 43.3±3.04 NS NS NS
Supplemental 44.3±3.25 45.0±3.25
Tb.Th, mm Adequate 0.051±0.003 0.047±0.003 NS NS NS
Supplemental 0.047±0.003 0.048±0.003
Tb.N, mm Adequate 5.9±0.64 7.5±0.60 .05 .02 NS
Supplemental 7.2±0.60 8.7±0.60
Tb.Sp, mm Adequate 0.120±0.007 0.089±0.007 .009 b.001 NS
Supplemental 0.096±0.007 0.075±0.007
Femur neck
BV/TV, % Adequate 61.4±1.40 59.4±1.29 NS NS NS
Supplemental 59.4±1.40 59.7±1.21
BS/BV,
mm2/mm3
Adequate 13.9±0.99 b 18.5±0.92 a NS NS 0.005
Supplemental 16.0±0.99 ab 14.7±0.86 b
Tb.Th, mm Adequate 0.144±0.007 b 0.112±0.006 a NS NS 0.003
Supplemental 0.127±0.007 ab 0.138±0.006 b
Tb.N, mm Adequate 4.27±0.32 b 5.53±0.29 a NS NS 0.01
Supplemental 4.74±0.32 ab 4.37±0.27 b
Tb.Sp, mm Adequate 0.091±0.006 0.077±0.006 NS NS NS
Supplemental 0.087±0.006 0.075±0.007
1Values are expressed as mean±S.E.M., n=6–7/group. Means without a common letter
differ, Pb.05. NS, PN.05. Abbreviations: BS/TV – bone surface to volume; BV/TV – bone
volume density; CON – control; FA – folic acid; ISO – soy isoﬂavones; NS – not signiﬁcant;
Tb.Th – trabecular thickness; Tb.N – trabecular number; Tb.Sp – trabecular separation.
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were no differences in BS/BV or Th.Th. at the lumbar spine between
groups (Table 1). Female offspring exposed to supplemental FA hadFig. 3. Serummarkers of metabolismmeasured in 4month old female CD-1 mice whosemother
PND 1-10 were treated with subcutaneous injections of corn oil. Values are expressed as mean
ACTH – adrenocorticotropic hormone; CON – control; FA – folic acid; ISO – soy isoﬂavones; IG
factor kappa-β ligand.higher (P=.05) Tb.N. and lower (P=.009) Tb.Sp. of LV4 than females
exposed to adequate FA. Females exposed to ISO had higher (P=.02)
Tb.N. and lower (Pb.001) Tb.Sp. of LV4 than females exposed to corn
oil. There were no differences in BV/TV or Tb.Sp. at the femur neck
between groups. There was an overall interaction effect (FA × ISO)
(Pb.05) on femur neck BS/BV, Tb.Th. and Tb.N. Female offspring
exposed to adequate FA+ISO had higher (P=.005) BS/BV, lower (P=
.003) Tb.Th. and higher (P=.012) Tb.N. compared to mice exposed to
supplemental FA+ISO or adequate FA.
3.4. Early life exposure to adequate FA+ISO results in higher serum OPG
and IGF-I in female mice at adulthood
Exposure to supplemental FA+ISO or supplemental FA alone did
not result in altered serum biochemistry compared to adequate FA.
Female offspring exposed to adequate FA+ISO had higher serum OPG
(FA, P=.0075; ISO, P=.0173; FA × ISO, P=.0299) and IGF-I (Pb.05)
concentrations than all other treatment groups (Fig. 3). In addition,
female offspring exposed to adequate FA+ISO had a two-fold higher
(FA, P=.0067; ISO, P=.0061; FA × ISO, P=.05) ratio of OPG to RANKL
compared to all other treatment groups (Fig. 3). There were no
differences in serum RANKL, osteocalcin or ACTH concentrations
among groups (Fig. 3).
3.5. Early life exposure to adequate FA+ISO or supplemental FA without ISO
suppresses DNAmethyltransferase expression in long bones of adult femalemice
Real-time RT-PCR analyses revealed that early life exposure to
supplemental FA+ISO does not alter the expression of DNA methyl-
transferase (i.e. Dnmt1, Dnmt3a or Dnmt3b) in adult bone tissue.
However, female offspring exposed to adequate FA+ISO or supple-
mental FA had signiﬁcantly (Pb.05) lower Dnmt3a expression in bone
than females exposed to adequate FA without ISO (Fig. 4).s’were fed adequate or supplemental FA during pregnancy and lactation, and who from
s±S.E.M., n=10–12/group. Bars without a common letter differ, Pb.05. Abbreviations:
F – insulin growth factor; OPG – osteoprotegrin; RANKL – receptor activator of nuclear
Fig. 4. Expression of DNA methyltransferases (Dnmt1, Dnmt3a and Dnmt3b) in bones of 4 month old female CD-1 mice whose mothers’were fed adequate or supplemental FA during
pregnancy and lactation, and who from PND 1-10 were treated with subcutaneous injections of corn oil or ISO. Values are expressed as mean±S.E.M., n=6/group. Bars without a
common letter differ, Pb.05. Abbreviations: CON – control; FA – folic acid; ISO – soy isoﬂavones.
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Since Dnmt3a plays a role in establishing DNAmethylation patterns
early in development and has the potential to modulate the expression
of many genes, microarray analyses were performed to identify gene
candidates. Out of 45281 genes represented on the Mouse WG-6v2r3Fig. 5. Microarray analysis shows differential signatures in gene expression of 6-week old fema
and lactation, andwho fromPND1-10were treatedwith subcutaneous injections of corn oil or I
statistically different between the groups. The heatmap visualizes the pattern of gene expressio
to the 949 genes and the displayed intensities are the differences among the groups. The expr
standard deviation for visualization purposes. Differences with expression levels greater than
diagram showing the number of genes that are up- or down-regulated in femurs of 6-week old f
of FA during pregnancy and lactation and were treated with either corn oil or ISO treatment farray, 30269 probeswere analyzed.Out of theseprobes, 949 geneswere
identiﬁed to be statistically different among groups (Fig. 5A). Out of
these genes, 405, 118 and 113 genes were uniquely differentially
expressed (Pb.05) by early life exposure to supplemental FA+ISO,
adequateFA+ISOand supplemental FA, respectively (Fig. 5B). Fromthis
cluster, 37 genes were differentially expressed by all three treatmentsle CD-1 mice whose mothers’ were fed adequate or supplemental FA during pregnancy
SO. (A) Expression proﬁle and clustering of 949 signature genes thatwere identiﬁed to be
n values (log2 transformed hybridization intensities). There are 949 rows corresponding
ession value for each difference is normalized across the samples to zero mean and one
the mean are colored in red and those below the mean are colored in green. (B) A Venn
emaleswhosemotherswere fed a diet containing either adequate or supplemental levels
rom PND 1–10. n=6/group.
Table 2
List of differentially expressed genes categorized according to gene ontology
Group Gene ontology Number of
genes affected
Direction of
change
Supplemental
FA+ISO
DNA recombination 9 ↓ 9
Double strand break repair 6 ↓ 6
DNA repair 12 ↓ 12
Response to DNA damage stimulus 13 ↓ 13
DNA metabolic process 18 ↓ 18
Cellular response to stress 14 ↓ 14
Cellular macromolecule
metabolic process
71 ↓ 71
Somatic cell DNA recombination 5 ↓ 5
Somatic diversiﬁcation of
immune receptors via germline
5 ↓ 5
Recombination repair 3 ↓ 3
Double-strand break repair
via homologous recombination
3 ↓ 3
V(D)J recombination 4 ↓ 4
Somatic diversiﬁcation of
immune receptors
5 ↓ 5
Nuclear part 23 ↓ 23
Uracil DNA N-glycosylase activity 2 ↓ 2
Adequate
FA+ISO
Isomerase activity 8 ↑ 8
Supplemental
FA
Ribosome 7 ↓ 7
Organellar 4 ↓ 4
Mitochondrial ribosome 4 ↓ 4
Ribonuclear complex 9 ↓ 9
Mitochondrial matrix 4 ↓ 4
Table 3
List of differentially expressed genes in mouse clones that may explain how adequate
FA+ISO, supplemental FA and supplemental FA+ISO, program bone outcomes at adulthood
Gene symbol Full name Gene description Fold
change
Supplemental
FA+ISO
LOC100046770 Histone
macroH2A1.2
▪ Regulates stable × chromosome
inactivation by inhibiting histone
acetylation, interfering with DNA
remodeling complexes, and
inactivating transcription
factor binding
−1.29
Top2a DNA
topoisomerase
2-alpha
▪ Controls and alters the topologic
states of DNA during transcription
by catalyzing the transient breaking
and rejoining of two strands of
duplex DNA; involved in chromosome
condensation, chromatid separation,
and the relief of torsional stress that
occurs during DNA transcription
and replication.
−1.32
P4hb Protein disulﬁde-
isomerase
▪ Catalyzes the formation, breakage
and rearrangement of disulﬁde bonds
1.18
PTHr1 Parathyroid
hormone receptor
▪ Regulates calcium ion homeostasis
through activation of adenylate
cyclase and phospholipase C; when
activated by PTH stimulates
bone resorption
1.63
Ctnnb1 β-Catenin ▪ Part of a complex of proteins that
constitute adherens junctions; it
anchors the actin cytoskeleton and
play a role in transmitting the contact
inhibition signal that causes cells to
stop dividing once the epithelial sheet
is complete
1.76
Phospho1 Phosphatase,
orphan 1
▪ Involved in the generation of
inorganic phosphate for bone
mineralization
1.80
Irf-4 Interferon
regulatory factor
▪ Transcription factor that plays a
role in cell growth, differentiation
and immune function; modulates
IGFBP-7 transcription
−1.20
Crebl1 cAMP response
element binding
protein
▪ Stimulates transcription and
indirectly regulates IGFBP-7
−1.21
Adequate
FA+ISO
Top1mt DNA
topoisomerase I
▪ Releases the super coiling and
torsional tension of DNA
1.29
P4hb Protein disulﬁde-
isomerase
▪ Catalyzes the formation, breakage
and rearrangement of disulﬁde bonds.
1.10
Ppia Peptidylprolyl
isomerase A
▪ Accelerates protein folding 1.10
NPY Neuropeptide Y ▪ Neurotransmitter that promotes
bone formation by increasing
osteoblast number
−5.67
Supplemental FA
alone
Irf-5 Interferon
regulatory factor
▪ Transcription factor that plays a role
in cell growth, differentiation and
immune function; modulates IGFBP-7
transcription
1.19
P4hb Protein disulﬁde-
isomerase
▪ Catalyzes the formation, breakage
and rearrangement of disulﬁde bonds
1.26
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important modulator in skeletal morphogenesis.
Gene ontology revealed that compared to adequate FA, exposure to
supplemental FA+ISO or supplemental FA alone reduces the expres-
sion of genes involved in cell cycle regulation (Tables 2 and 3). In
contrast, exposure to adequate FA+ISOup-regulates the expression of
8 genes in the ‘isomerase activity’ pathway (Table 2). These genes are
involved in protein folding, release of super-coiling and torsional
tension of DNA, rearrangement of disulﬁde bonds and regulation of
different receptors (Table 3). Analysis of microarray data also
demonstrated that the expression of mRNA encoding NPY was the
second most highly altered gene with a 5.67-fold down-regulation in
mice fed adequate FA+ISO (Table 3). This ﬁnding was conﬁrmed by
real-time PCR analysis which showed that female mice exposed to
adequate FA+ISO or supplemental FA have signiﬁcantly lower NPY
mRNA expression at the femur than female mice exposed to adequate
FA (Fig. 6).
4. Discussion
Contrary to our hypothesis, exposure to supplemental FA+ISO did
not provide greater beneﬁts to bone health than either treatment
alone. Rather, female offspring whose mothers were fed an adequate
FA diet, and were treated with ISO for the ﬁrst 10-days of life had
higher BMD, more bone volume (BV/TV) and greater trabecular
connectivity (↑Tb.N. ↓Tb.Sp.) at the femur neck and lumbar spine than
female offspring exposed to adequate FA alone. The higher mineral
content and structural improvements resulted in stronger bones. In
addition, these mice had higher levels of bone formation markers (i.e.
OPG and IGF-I). Exposure to supplemental FA+ISO or supplemental
FA alone provided some beneﬁts to female bone but the effects were
less pronounced than those induced by adequate FA+ISO. For
example, female mice exposed to supplemental FA with or without
ISO did not show any changes in bone formation markers or
improvements in bonemicroarchitecture at the femur neck compared
to females exposed to adequate FA alone.Based on these observations we hypothesized that ISO and FAmay
be inducing their effects through the same mechanism, and that
combining these two interventions may activate a negative feedback
control system that attenuates or prevents the induction of biological
effects. It is generally accepted that endocrine factors have continuous
feedback systems that work together to signal the glands to regulate
the amount of hormones present in circulation. While FA and ISO are
Fig. 6. Expression of NPY, PTHr1 and Ctbb1 in bones of 4month old female CD-1micewhosemothers’were fed, adequate or supplemental FA during pregnancy and lactation, andwho from
PND1-10were treatedwith subcutaneous injectionsof cornoil or ISO. Total RNA isolated fromboneandquantitative real-timePCR analyses conﬁrmed that femalemiceexposed toadequate
FA+ISOor supplemental FAhave reducedNPYgeneexpression in comparison tomice exposed to adequate FAwithout ISO. PTHr1 andCtnbb1were not signiﬁcantlydifferent among groups.
Values are expressed as mean±S.E.M., n=6/group. Bars without a common letter differ, Pb.05. Abbreviations: CON – control; FA – folic acid; ISO – soy isoﬂavones.
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[32] and indirectly affect the expression of hormones, enzymes
and transcription factors. Thus, it is possible that when given in
combination during sensitive stages of development exposure to
supplemental FA+ISO alters gene expression in such a way that
prevents or attenuates the induction of biological effects induced by
either treatment alone.
To understand potential mechanisms by which adequate FA+ISO
or supplemental FA alone result in stronger femurs and lumbar
vertebra, we ﬁrst measured the expression of DNAmethyltransferases
in long bones of adult female mice. Exposure to adequate FA+ISO or
supplemental FA alone equally suppressed Dnmt3a expression in
bone. Since Dnmt3a plays a role in setting up DNA methylation
patterns during development and can alter the expression of many
genes, we performed bone microarray analyses to compare the gene
expression proﬁles among groups.
The ﬁnding that female mice exposed to supplemental FA+ISO,
adequate FA+ISO or supplemental FA alone had 3% of their genes
changed in bone at 6 weeks of age provided evidence that FA and ISO
improve bone through an epigenetic mechanism. As expected, female
mice exposed to supplemental FA+ISO had a higher number of
differentially expressed genes (560 genes) than those exposed to
adequate FA+ISO (260 genes) or supplemental FA (259 genes)
(Fig. 5). Importantly, the differentially expressed genes of femalemice
exposed to supplemental FAwith orwithout ISOwere involved inDNA
synthesis, stability, integrity or repair – supporting the principle
function of folate. However, based on the differences in bone outcome
measures (i.e. BMD, bone structure, bone strength and serummarkers
of bone turnover) among groups, we knew that females exposed to
adequate FA+ISOhad someunderlying change thatwas not present in
mice exposed to adequate FA or supplemental FA+ISO. In examining
microarray analyses we discovered that only females exposed to
adequate FA+ISO had a 5.7-fold lower expression of neuropeptide Y
(NPY) at the femur than females exposed to adequate FA alone. This
ﬁnding was also conﬁrmed using quantitative real-time PCR analyses
and further showed that NPY is also down-regulated in femurs of
females exposed to supplemental FA alone. Thepromoter ofNPY spans
over 246 base pairs and has 3 transcription factor binding sites (NGF-
RE, AP-2 and NGFI-A) that contain CpG islands [33], which indicates
that imprinting of female bonemay in part bemediated by NPY. Out of
949 genes that were identiﬁed to be differentially expressed in the
mouse genome, NPY was the second most highly altered gene. The
gene that was most profoundly altered in mRNA expression was
A530055J02Rik, which is a non-coding RNA that was equally
suppressed in all three treatment groups (supplemental FA+ISO,adequate FA+ISO, supplemental FA). Thus, NPY rather than
A530055J02Rik is the more likely candidate responsible for bone
improvement of female mice exposed to adequate FA+ISO or
supplemental FA alone.
Widely expressed in the central and peripheral nervous system,
NPY is an important regulator of many physiological processes,
including bone and energy metabolism [34]. In bone, NPY inhibits
osteoblast formation [35], decreases osteoblast cell number [36],
reduces the expression of late stage genes that promote bone
formation (i.e. osteoclacin and DMP-1) [37] and decreases mineral
deposition [38]. Thus, the ﬁnding that female CD-1 mice exposed to
adequate FA+ISO had undetectable levels of NPYmRNA expression in
bone tissue at 6-weeks of age suggests that NPY may largely be
responsible for the observed improvements in bone tissue (i.e. ↑ BMD,
↑ Tb.N, ↑ OPG/RANKL ratio, ↑ bone strength). Moreover, taking that
genes are usually not expressed in isolation but rather in the context of
other genes and their products, cells and tissues in a temporal and
special dimension, the ﬁnding that NPY is down-regulated in bone
tissue suggests that NPY gene expression may also be altered in
other tissues. Until recently, scientists have viewed each tissue as
an independent commodity, but emerging ﬁndings indicate that
signaling pathways exist between tissues so studyingwhole-organism
physiology is highly important. From published literature we know
that there is a degree of connection between theNPY-mediated changes
in bone and energy homeostasis [34]. However, the degree to which
these processes are interrelated remains to be elucidated. In this study,
we identiﬁed that females exposed to adequate FA+ISO during
development have higher body weight from 4 through 16 weeks of
age than those exposed to adequate FA alone. Although this ﬁnding has
previously been shown [28], this study is the ﬁrst to demonstrate that
ISO-induced effects on bodyweight depend on the level of FA exposure.
Female CD-1 mice exposed to supplemental FA+ISO did not have
signiﬁcant changes in body weight compared to females exposed to
supplemental FA. Therefore, it seems that both bone and adipose tissue
respond most profoundly to adequate FA+ISO during development.
In summary, female mice exposed to adequate FA+ISO or
supplemental FA alone had signiﬁcant improvements in BMD, trabe-
cular connectivity and resistance to fracture at the femur and lumbar
spine when compared to females exposed to adequate FA alone, while
improvements induced by supplemental FA+ISO were limited to
higher BMD, trabecular connectivity and peak load at the lumbar spine.
Based on the gene expression proﬁles we believe that these functional
outcomes are inpart a reﬂectionof epigenetic or transcriptomic changes
induced by suppression of Dnmt3a that include a signiﬁcant down
regulation in NPY.
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